Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.34 per share a year ago. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback